• Company
• Latecomer psoriasis treatment 'Bimzelx' launches
• by Whang, byung-woo Nov 22, 2024 05:55am

• Company
• ‘Global Bio M&A Trends: Fewer New Drugs, More CDMOs’
• by Kim, Jin-Gu Nov 22, 2024 05:55am

• Company
• New CGRP antagonist 'eptinezumab' expected to be marketed
• by Eo, Yun-Ho Nov 21, 2024 05:46am

• Company
• ‘Use of Prevenar 20 will rise to address the unmet need'
• by Son, Hyung Min Nov 20, 2024 06:08am

• Company
• Drug switching policy for atopic dermatitis fails to address
• by Whang, byung-woo Nov 20, 2024 06:08am

• Company
• Returned out-licensing, Daewoong's autoimmune disease drug
• by Son, Hyung Min Nov 19, 2024 06:13am

• Company
• Three months after Pluvicto launch
• by Moon, sung-ho Nov 19, 2024 06:13am

• Company
• Imfinzi passes first step to reimb in KOR… key is the price
• by Whang, byung-woo Nov 19, 2024 06:13am

• Company
• Mounjaro aims for 'diabetes·obesity' synergy
• by Whang, byung-woo Nov 19, 2024 06:12am

• Company
• Academia pushes for Tagrisso’s reimbursement expansion
• by Moon, sung-ho Nov 19, 2024 06:12am